Finanzen von Zevra Therapeutics Inc (ZVRA)ZVRAZevra Therapeutics Inc

Evaluating the bottom line, Zevra Therapeutics, Inc. maintains a gross margin of 95.36%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 42.30%, while the net margin is 22.07%. These profitability ratios, combined with a Return on Equity (ROE) of 34.19%, provide a clear picture of how effectively ZVRA converts its operational activities into shareholder value.

In the context of the broader market, ZVRA competes directly with industry leaders such as OLMA and NVCT. With a market capitalization of $609.87M, it holds a significant position in the sector. When comparing efficiency, ZVRA's gross margin of 95.36% stands against OLMA's N/A and NVCT's N/A. Such benchmarking helps identify whether Zevra Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Zevra's financial performance shows a strong upward trend in revenue, with Q2 2026 revenue at $39.7 million, a 53% increase year-over-year. The gross margin is also impressive at 95.36% for Q2 2026, indicating efficient cost management and strong profitability potential.